India Cancer Immunotherapy Market

India Cancer Immunotherapy Market Size Expands at Significant CAGR of 6.39% During 2024–2030, Reaching USD 102.11 Billion by 2030

Published | 02 February 2024

India Cancer Immunotherapy Market is flourishing because of the increasing prevalence of cancer, government initiatives & funding, and rising healthcare expenditure.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated the India Cancer Immunotherapy Market size at USD 98.37 billion in 2023. During the forecast period between 2024 and 2030, BlueWeave expects the India Cancer Immunotherapy Market size to grow at a significant CAGR of 6.39% reaching a value of USD 102.11 billion by 2030. As per the Indian Council of Medical Research – National Cancer Registry Programme (ICMR-NCRP), the estimated number of incidences of cancer cases in the country in 2022 was 14,61,427. Supportive government initiatives and funding for cancer research and treatment play a pivotal role. Investments in healthcare infrastructure and programs that promote immunotherapy adoption contribute to market growth.  The Central Government has implemented the Strengthening of Tertiary Cancer Care Centres Facilities Scheme to improve cancer treatment facilities. The plan has approved 19 state cancer institutes (SCIs) and 20 tertiary care cancer centres (TCCCs). Increased healthcare spending, both by the government and individuals, fuels the adoption of advanced cancer treatments. This includes immunotherapies that offer promising outcomes in combating cancer

Opportunity: Advancements in Research and Development  

Ongoing research and development activities in cancer immunotherapy provide prospects for the introduction of novel and more effective immunotherapeutic drugs. This may improve therapy options and outcomes for cancer patients in India. Novel therapy techniques, such as immune checkpoint inhibitors and adoptive cell treatments, are emerging as viable options for cancer patients in India. The Central Drugs Standard Control Organisation (CDSCO) has approved CAR-T (Chimeric Antigen Receptor-T) cell therapy, a ground-breaking treatment for relapsed/refractory (r/r) B-cell lymphomas and leukaemia, paving the way for the commercial launch of indigenous NexCAR19 in the country. ImmunoACT, an IIT Bombay incubated firm, developed the treatment.

Impact of Geopolitical Tension on India Cancer Immunotherapy Market

Geopolitical conflicts may cause interruptions in the pharmaceutical supply chain, compromising the availability of critical chemicals and medications. Political uncertainty may cause changes to regulatory frameworks, influencing medication approval processes and market access for immunotherapeutic treatments. Geopolitical instability may have an impact on foreign healthcare investments and funding, as well as cancer immunotherapy research and development initiatives. Political tensions can cause changes in trade policies, influencing the import and export of pharmaceutical products and potentially limiting access to cancer immunotherapies. Collaborations for multinational clinical trials, a critical part of drug development, may confront problems due to geopolitical tensions, affecting the progression of new cancer immunotherapy treatments.

Sample Request @

India Cancer Immunotherapy Market – By End User

Based on end user, the India cancer immunotherapy market is segmented into hospitals, cancer research centers, and clinics. The hospital segment dominates the Indian cancer immunotherapy market. This is attributable to a number of variables, including a rise in the number of hospital admissions for cancer treatment, expanded hospital penetration across the country, and a greater preference for hospital care. Furthermore, the growing number of government and private hospitals, as well as the increasing use of cutting-edge technologies, add to hospitals' dominance in the cancer immunotherapy industry. Hospitals have the infrastructure and resources necessary to successfully deliver and monitor immunotherapy therapies.

India Cancer Immunotherapy Market – By Region

Regionally, the India Cancer Immunotherapy Market is segmented as North India, South India, East India, and West India. North India is expected to grow during the forecast period. North India, particularly Delhi and surrounding regions, boasts advanced healthcare infrastructure with leading hospitals and research centers. This facilitates the adoption and accessibility of cancer immunotherapy treatments. North India attracts a significant number of medical tourists seeking specialized cancer treatments, including immunotherapy. The presence of renowned healthcare institutions contributes to the region's dominance.

Competitive Landscape

Major players operating in the India Cancer Immunotherapy Market include Astellas Pharma Inc., AstraZeneca, Bayer AG, Bristol-Myers Squibb, Lilly, F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Novartis AG, Pfizer Inc., Gilead Sciences, Inc, GSK plc, Johnson & Johnson, Sanofi. To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.

Don’t miss the business opportunity in the India Cancer Immunotherapy Market. Consult our analysts to gain crucial insights and facilitate your business growth.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of India Cancer Immunotherapy Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in India Cancer Immunotherapy Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

About Us

BlueWeave Consulting provides comprehensive Market Intelligence (MI) Solutions to businesses regarding various products and services online and offline. We offer all-inclusive market research reports by analyzing qualitative and quantitative data to boost the performance of your business solutions. BlueWeave has built its reputation by delivering quality inputs and nourishing long-lasting relationships with its clients. We are one of the promising digital MI solutions companies providing agile assistance to make your business endeavors successful.

Contact Us:

BlueWeave Consulting & Research Pvt Ltd

+1 866 658 6826 | +1 425 320 4776 | +44 1865 60 0662